Synthesis of vitamin D3 derivatives with nitrogen-linked substituents at A-ring C-2 and evaluation of their vitamin D receptor-mediated transcriptional activity
作者:Junko Abe、Yu Nagai、Rui Higashikuni、Keisuke Iida、Takatsugu Hirokawa、Hazuki Nagai、Kaichiro Kominato、Toshio Tsuchida、Michiko Hirata、Masaki Inada、Chisato Miyaura、Kazuo Nagasawa
DOI:10.1039/c2ob26017d
日期:——
Binding of a series of novel 1α,25-dihydroxyvitamin D3 (1,25-VD3) derivatives, having a nitrogen-linked substituent at the 2α- or 2β-position of the A-ring (2-N-substituted compounds), with the vitamin D receptor (VDR) was investigated by means of computational docking studies. Selected compounds were synthesized by coupling A-ring synthons 6 and/or 7 with CD-ring-bearing bromomethylene 5 under Trost's conditions. The 2α- and 2β-stereoisomers of the A-ring synthons were synthesized from L-serine (8) as a single chiral source by installing vinyl and propargyl groups at opposite ends of the molecule. The activity of the obtained compounds was evaluated by means of a luciferase-based VDR transcriptional activity assay in NIH3T3 cells. Relatively small substituents incorporating a hydrogen-bonding donor, i.e., NHAc and NHMs, were effective for eliciting VDR transcriptional activity, and 2β-NHMs-1,25-VD3 (Xa) showed the highest activity, being more potent than 1,25-VD3. Derivatives with bulky substituents were inactive. These new insights into the structure–activity relationships of 1,25-VD3 derivatives may be helpful in separating the various biological activities of 1,25-VD3 and in generating novel therapeutic drug candidates.
一系列新型 1α,25-二羟基维生素 D3 (1,25-VD3) 衍生物的结合,在 A 环的 2α- 或 2β- 位(2-N-取代的化合物)具有氮连接的取代基,通过计算对接研究对维生素 D 受体 (VDR) 进行了研究。通过在 Trost 条件下将 A 环合成子 6 和/或 7 与带有 CD 环的溴亚甲基 5 偶联来合成选定的化合物。 A 环合成子的 2α- 和 2β- 立体异构体是通过在分子的相对末端安装乙烯基和炔丙基,以 L-丝氨酸 (8) 作为单一手性来源合成的。通过在 NIH3T3 细胞中基于荧光素酶的 VDR 转录活性测定来评估所获得的化合物的活性。包含氢键供体的相对较小的取代基,即 NHAc 和 NHM,可有效引发 VDR 转录活性,2β-NHMs-1,25-VD3 (Xa) 显示出最高的活性,比 1,25- 更有效。 VD3。具有大取代基的衍生物没有活性。这些对 1,25-VD3 衍生物结构-活性关系的新见解可能有助于分离 1,25-VD3 的各种生物活性和产生新型候选治疗药物。